One‐year results of simultaneous laser in situ keratomileusis and small‐aperture corneal inlay implantation for hyperopic presbyopia: Comparison by age. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Tomita, Minoru; Waring, George O.
• Is Part Of: Journal of cataract and refractive surgery. Volume 41:Issue 1(2015)
• Publication Date: 2015-01
• Subjects: 617.7
• DOI: 10.1016/j.jcrs.2014.05.037
• Languages: English
• ISSNs: 0886-3350

Abstract

Abstract : Purpose : To compare by age the safety, efficacy, and patient satisfaction after simultaneous laser in situ keratomileusis (LASIK) and small‐aperture corneal inlay implantation (Kamra) for hyperopic presbyopia. Setting : Shinagawa LASIK Center, Tokyo, Japan. Design : Retrospective comparative cohort study. Methods : Simultaneous LASIK and small‐aperture corneal inlay implantation were performed in the nondominant eye of hyperopic presbyopic patients with astigmatism. Patients were divided into groups by age as follows: Group 1 (40 to 49 years), Group 2 (50 to 59 years), and Group 3 (60 to 65 years). The uncorrected (UDVA) and corrected (CDVA) distance visual acuities, uncorrected near visual acuity (UNVA), and patient questionnaire results were compared. Results : The study evaluated 277 eyes of 277 patients. All groups achieved a mean UDVA of 20/20, with Group 1, Group 2, and Group 3 gaining 1 line, 2 lines, and 3 lines, respectively. The mean UNVA was J2 with 4 lines gained in Group 1 and J3 with 5 lines gained in Group 2 and Group 3. The mean CDVA and corrected near visual acuity remained the same as at baseline. Conclusions : Simultaneous LASIK and small‐aperture corneal inlay implantation for hyperopic presbyopia was a safe and effective treatment option. Although the outcomes were comparable between groups, Group 3 had the largest gain in UDVA and UNVA and the highest patient satisfaction, despite having the lowest reduction in dependence on reading glasses. Taking age into account might help achieve optimum postoperative outcomes and improved patient satisfaction. Financial Disclosure : Dr. Tomita is a consultant to Ziemer Ophthalmic Systems AG, Acufocus, Inc., and Schwind eye‐tech‐solutions GmbH and Co. KG. Dr. Waring is a consultant to Acufocus, Inc.